Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X:
“Metastatic NSCLC without oncogenic alterations
ASCO Educational Book
ICI as Monotherapy
ICI as Combination Treatment
ICI-ICI Combination Treatments
Clinical Decision Questions:
Best Approach in PD-L1≥50%
Role for Dual Checkpoint Blockade
Discontinuation Strategies in Long-term Responders to ICI
Second-Line Treatments
Future Approaches
Antibody-drug Conjugates
Chemotherapy-free First-Line Treatments.”
Visit the article website.
Source: Erman Akkus/X
